Patent application number | Description | Published |
20090149496 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL - The invention relates to the use of Kv1.5 inhibitors for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in high mountains, acute and chronic lung disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer. | 06-11-2009 |
20120232002 | SLOW-ACTING INSULIN PREPARATIONS - Aqueous pharmaceutical formulations with an insulin analog, comprising
| 09-13-2012 |
20120252724 | INSULIN PREPARATIONS CONTAINING METHIONINE - The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus. | 10-04-2012 |
20120252852 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY - The invention relates to a pharmaceutical composition comprising methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 10-04-2012 |
20140018398 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY - The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 01-16-2014 |
20140221285 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-07-2014 |
20150190475 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART - Stabilized pharmaceutical formulations of insulin aspart are disclosed. | 07-09-2015 |
20150216941 | Stabilized Pharmaceutical Formulations of Insulin Analogues and/or Insulin Derivatives - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-06-2015 |
20150216981 | Stabilized Pharmaceutical Formulations of Insulin Analogues and/or Insulin Derivatives - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-06-2015 |